Trials / Completed
CompletedNCT03355820
A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study
Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects From the HPV-058 Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 228 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 17 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the persistence of immune response in subjects who received the HPV-16/18 vaccine, seven to eight years after the last dose of primary vaccination in the HPV-058 study. No new subjects will be enrolled in this extension study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Blood sampling for antibody determination | In order to assess the persistence of immune responses seven to eight years after the last vaccine dose against HPV-16/18, a blood sample (\~5 mL) will be taken from all the subjects, at Day 1. |
Timeline
- Start date
- 2018-02-28
- Primary completion
- 2018-06-29
- Completion
- 2018-06-29
- First posted
- 2017-11-28
- Last updated
- 2020-11-19
- Results posted
- 2019-06-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03355820. Inclusion in this directory is not an endorsement.